Download Free Medical Barretts Esophagus PowerPoint Presentation

Barretts Esophagus PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Esophageal Cancer, which is titled "Barretts Esophagus", to know about the importance of Barretts Esophagus, its diagnosis, its screening, its surveillance, diagnosis and management of dysplasia, and endoscopic therapy for Barretts related neoplasia.

Tags : Esophageal Cancer, Barretts Esophagus, diagnosis, screening, surveillance, diagnosis, management, dysplasia, endoscopic therapy, neoplasia

Published on : May 13, 2021 | Views : 2020 | Downloads : 12

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Minesh Mehta, PGY-4 University of Louisville Department of Gastroenterology Barrett’s Esophagus
Slide 2-

Importance of Barrett’s Esophagus Diagnosis Screening Surveillance Diagnosis and Management of Dysplasia Endoscopic Therapy for Barrett’s Related Neoplasia Outline
Slide 3-

Acquired condition in response to Gastro-esophageal reflux leading to columnar lined epithelium in the distal esophagus Intestinal metaplasia, characterized by goblet cells, is biologically unstable with greatest risk of neoplastic progression Making it a major risk factor in development of esophageal adenocarcinoma Incidence of EAC rising rapidly in western countries Significance of BE Wang KK, Sampliner RE, Practice Parameters Committee of the American College of G. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-797.
Slide 4-

Change in the distal esophageal epithelium of any length that can be recognized as columnar type mucosa at endoscopy and is confirmed to have intestinal metaplasia by biopsy of the esophagus Clearly visible endoscopically above the GEJ(>1cm) and confirmed histo-pathologically with distal esophageal biopsies of columnar lined epithelium only Definition of BE
Slide 5-

http://library.med.utah.edu/WebPath/GIHTML/GIIDX.html#1
Slide 6-

Must distinguish BE from Irregular Z-line Where the squamo-columnar junction appears with tongues of columnar epithelium less than 1cm with no confluent columnar lined segments Biopsies are generally NOT RECCOMENDED for Irregular Z-line If done, then label as GEJ not esophageal biopsies Endoscopic Diagnosis of BE
Slide 7-

Wallner B, Sylvan A, Janunger KG. Endoscopic assessment of the "Z-line" (squamocolumnar junction) appearance: reproducibility of the ZAP classification among endoscopists. Gastrointest Endosc 2002;55:65-69. REGULAR Z - Line Irregular Z - Line
Slide 8-

Must accurately delineate the GEJ by detecting the proximal end of the longitudinal Gastric Folds with minimal air insufflation Columnar epithelium should be visible endoscopically (minimum of 1cm) above the GEJ to diagnose as BE
Slide 9-

ppt slide no 9 content not found
Slide 10-

Should be done using the Prague Criteria Which assesses the circumferential (C) and maximal (M) extent of endoscopically visualized Barrett’s Segment Diaphragmatic Pinch and Proximal End of the Gastric Folds The presence and location of visible lesions should be recorded according to Paris Classification Endoscopic Reporting of BE
Slide 11-

ppt slide no 11 content not found
Slide 12-

Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
Slide 13-

Developed by the Barrett’s Oesophagus Subgroup of the International Working Group for the Classification of Reflux Oesophagitis (IWGCO)
Slide 14-

Recognize Hiatus Hernia
Slide 15-

http://www.quality-in-endoscopy.org/assets/download/pdf/reports/qine30/04_1_LT_Bisschops.pdf Circumferential Extent of Suspected Barrett’s
Slide 16-

http://www.quality-in-endoscopy.org/assets/download/pdf/reports/qine30/04_1_LT_Bisschops.pdf Maximal Extent of Suspected Barrett’s
Slide 17-

Developed by the Barrett’s Oesophagus Subgroup of the International Working Group for the Classification of Reflux Oesophagitis (IWGCO)
Slide 18-

Minimum of 8 biopsies provides adequate assessment of Intestinal Metaplasia Starting distally 1-2cm above GEJ, 4 quadrant random biopsies should be done every 2cm while advancing proximally Targeted biopsies of visible lesions (should be done before random biopsies) Ideally, erosive esophagitis should be healed prior to biopsies for BE to avoid missing short segments of columnar epithelium Biopsy Protocol Harrison R, Perry I, Haddadin W, McDonald S, Bryan R, Abrams K, Sampliner R, et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007;102:1154-1161. Hanna S, Rastogi A, Weston AP, Totta F, Schmitz R, Mathur S, McGregor D, et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006;101:1416-1420.
Slide 19-

To improve standard of care and ease of communication between experts, the use of a minimum dataset is recommended to record histo-pathologic findings Minimum Dataset
Slide 20-

ppt slide no 20 content not found
Slide 21-

Screening for BE in unselected population of patients with gastro esophageal reflux symptoms is not recommended Screening should be considered in patients with chronic GERD (> 13 years) and multiple risk factors including at least 3 of the following Age 50 or older White race Male sex Obesity Threshold of multiple risk factors should be lowered in those with a first degree relative with Barrett’s or esophageal adenocarcinoma Screening For BE
Slide 22-

Aim of surveillance is to detect cancer or pre-cancer at a stage when intervention may be curative Surveillance correlates with earlier staging and improved survival from cancer Endoscopic monitoring with histo-pathologic assessment of dysplasia is the only current method of surveillance Patients should have access to outpatient clinic to discuss diagnosis of BE and discussion of pros and cons of surveillance High resolution Endoscopy should be used for surveillance Surveillance
Slide 23-

Intestinal Gastric metaplasia or - A number of studies have reported a positive correlation between length of Barrett’s and risk for adenocarcinoma - Therefore, those with >3cm maximum segment of Barrett’s without dysplasia should be considered for repeat EGD every 2-3 years Surveillance of Non Dysplastic Barrett’s Esophagus
Slide 24-

Dysplasia should be reported as low or high grade (controversy over indefinite) Any grade of dysplasia should be confirmed by an expert or two independent pathologist Revised Vienna Classification for GI mucosal neoplasia standardizes diagnostic terminology into biologically similar groupings with scores of 1-5 depending on presence/absence of dysplasia or malignancy 1. Negative for Dysplasia 2. Indefinite for Dysplasia 3. Low Grade Dysplasia 4. High Grade Dysplasia 5. Submucosal Invasion of Adenocarcinoma Pathologic features and Reporting of Dysplasia
Slide 25-

Intestinal Metaplasia
Slide 26-

Higher Power
Slide 27-

Indefinite for Dysplasia
Slide 28-

Low Grade Dysplasia
Slide 29-

High Grade Dysplasia
Slide 30-

ppt slide no 30 content not found
Slide 31-

Booth CL, Thompson KS. Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments. J Gastrointest Oncol 2012;3:232-242.
Slide 32-

Esophageal adenocarcinoma
Slide 33-

Controversy exists for management of indefinite for dysplasia Rate of cancer progression in patients with indefinite for dysplasia was similar to non-dysplastic patients; however, if the indefinite for dysplasia was multifocal, the rate of progression was as high as in patients with LGD Younes M, Lauwers GY, Ertan A, Ergun G, Verm R, Bridges M, Woods K, et al. The significance of "indefinite for dysplasia" grading in Barrett metaplasia. Arch Pathol Lab Med 2011;135:430-432.
Slide 34-

Management of Low Grade Dysplasia – Prior to SURF Trial Data BSG ACG
Slide 35-

Obtain every 1 cm in patients with known dysplasia Biopsy Protocol for Known Dysplasia
Slide 36-

ppt slide no 36 content not found
Slide 37-

Primary outcome: occurrence of HGD or Adenocarcinoma anytime during 3 years following randomization Secondary outcomes: histological eradication of dysplasia and intestinal metaplasia, and adverse events
Slide 38-

Patients in Ablation group were less likely than the control group to progress to high-grade dysplasia or adenocarcinoma Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0% (95% CI, 14.1%-35.9%), with an NNT of 4.0 (95% CI, 2.8-7.1) Ablation reduced the risk of progression to adenocarcinoma by 7.4% (95% CI, 0.0%-14.7%), with an NNT of 13.6 (95% CI, 6.8-)
Slide 39-

ppt slide no 39 content not found
Slide 40-

Endoscopic ablative therapy is a superior management strategy to endoscopic surveillance in patients with Barrett’s esophagus and confirmed low-grade dysplasia Ablation treatment was generally safe with esophageal stricture being the most common complication (11.8%), requiring a median of 1 dilation Conclusions from SURF Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014;311:1209-1217.
Slide 41-

patients with LGD should have a repeat endoscopy in 6 months time If LGD is found in any of the follow up EGDs and is confirmed by an expert GI pathologist, the patient should be offered endoscopic ablation therapy https://youtu.be/X-9u-99HFOc 2015 Updated BSG Guideline for LGD
Slide 42-

If the possibility of high grade dysplasia has been raised, it is critical that a high-quality baseline endoscopy is done to map out any visible lesions and extent of dysplasia Endoscopic assessment will usually identify the area with the most advanced neoplasia. EMR should aim to resect all visible abnormalities. HGD and Barrett’s-related adenocarcinoma confined to the mucosa, endoscopic therapy is preferred over esophagectomy or endoscopic surveillance Management of High Grade Dysplasia
Slide 43-

Esophageal Wall
Slide 44-

Esophageal cancer staging
Slide 45-

ppt slide no 45 content not found
Slide 46-

ppt slide no 46 content not found
Slide 47-

ppt slide no 47 content not found
Slide 48-

ppt slide no 48 content not found
Slide 49-

ppt slide no 49 content not found
Slide 50-

Endoscopic therapy for Barrett’s neoplasia has been developed on the evidence that HGD and T1a EAC is associated with a low rate of lymph node metastasis: endoscopic and surgical series indicate a 0–10% risk in T1a cancer, while submucosal invasion carries a higher risk (up to 46%) ER should be considered the therapy of choice for dysplasia associated with visible lesions and T1a adenocarcinoma (Recommendation grade B)
Slide 51-

For patients at high surgical risk, endoscopic therapy can be offered as an alternative to surgery for treatment of good prognosis T1b adenocarcinomas (T1b sm1, well differentiated and without lymph vascular invasion). For T1b adenocarcinomas with involvement of the second sub-mucosal layer or beyond (T1b sm2–sm3), endoscopic therapy should not be considered curative
Slide 52-

In the presence of HGD or intramucosal cancer without visible lesions (flat HGD/intramucosal cancer), these should be managed with an endoscopic ablative technique. RFA currently has a better safety and side-effect profile and comparable efficacy. Eradication of residual Barrett’s esophagus after focal ER reduces the risk of metachronous neoplasia and is recommended.
Slide 53-

In patients treated for HGD, endoscopic follow-up is recommended every 3 months for 1 year and yearly thereafter. This should include biopsies at the GOJ and within the previous extent of the Barrett’s epithelium.
Slide 54-

ppt slide no 54 content not found